Olema Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-30.4M | $-31.0M | $-26.8M | $-21.5M | $-20.1M | $-28.3M | $-26.2M | $-22.7M |
| Depreciation & Amortization | $94.0K | $88.0K | $88.0K | $90.0K | $99.0K | $100.0K | $97.0K | $91.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $5.7M | $4.9M | $4.4M | $4.1M | $4.2M | $4.6M | $4.9M | $4.3M |
| Net Cash from Operating Activities | $-27.6M | $-23.5M | $-18.5M | $-22.7M | $-22.1M | $-20.4M | $-19.7M | $-18.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $6.0K | $153.0K | — | — | — | — | $173.0K | $139.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-4.9M | $-20.1M | $-30.9M | $-25.4M | $14.1M | $37.4M | $16.3M | $20.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $15.6M | $8.8M | $523.0K | $130.6M | $2.0M | $220.0K | $273.0K | $106.0K |
| Net Change in Cash | $-16.8M | $-34.8M | $-48.9M | $82.4M | $-6.0M | $17.2M | $-3.1M | $2.3M |
| Free Cash Flow | $-27.6M | $-23.6M | — | — | — | — | $-19.9M | $-18.1M |